:Thalidomide    (DrugBank: Thalidomide)

20 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症2
16クロウ・深瀬症候群3
20副腎白質ジストロフィー1
28全身性アミロイドーシス8
49全身性エリテマトーデス1
51全身性強皮症1
53シェーグレン症候群1
56ベーチェット病1
65原発性免疫不全症候群3
84サルコイドーシス1
85特発性間質性肺炎3
94原発性硬化性胆管炎1
96クローン病8
97潰瘍性大腸炎2
227オスラー病3
271強直性脊椎炎4
280巨大動静脈奇形(頚部顔面又は四肢病変)2
298遺伝性膵炎1
300IgG4関連疾患1
331特発性多中心性キャッスルマン病1

2. 筋萎縮性側索硬化症 [臨床試験数:508,薬物数:530(DrugBank:146),標的遺伝子数:170,標的パスウェイ数:221
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 508 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00231140December 200530/9/2005Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)Drug: Thalidomide (drug)Charite University, Berlin, GermanyNULLTerminated25 Years80 YearsBoth40Phase 2Germany
2NCT00140452February 200531/8/2005Phase II Study Using Thalidomide for the Treatment of ALSPhase II Study Using Thalidomide for the Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis;ALSDrug: ThalidomideDartmouth-Hitchcock Medical CenterCelgene CorporationCompleted18 Years80 YearsBoth24Phase 2United States

16. クロウ・深瀬症候群 [臨床試験数:12,薬物数:18(DrugBank:8),標的遺伝子数:5,標的パスウェイ数:79
Searched query = "Crow-Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 12 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN0000186602015/08/1717/08/2015Japanese POEMS syndrome with thalidmaide trial for compassionate useJapanese POEMS syndrome with thalidmaide trial for compassionate use - Japanese POEMS syndrome with thalidmaide trial for compassionate use (JPOST15) Crow-Fukase(POEMS) syndromeFPF300 (thalidomide)100-300mg/day,at bedtime +Dexamethasone 20mg/day (day1-4)

Duration:until the approval of thalidomide for POEMT syndrome
Chiba University Graduate School of MedicineNULLRecruiting20years-oldNot applicableMale and Female20Not selectedJapan
2JPRN-JMA-IIA0008422/03/201219/03/2012Japanese POEMS Syndrome with Thalidomide TrialJapanese POEMS Syndrome with Thalidomide Trial Crow-Fukase (POEMS) syndromeIntervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL.J-POST Clinical Trial OfficeHokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima UniversityCompleted>=20 YEARSNo LimitBOTH24Japan
3JPRN-JMA-IIA0004613/09/201006/09/2010Japanese POEMS Syndrome with Thalidomide TrialThalidomide Treatment for Crow-Fukase (POEMS) Syndrome: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Extension Phase to Evaluate the Long-term Safety Crow-Fukase (POEMS)syndromeIntervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL. Control intervention1:FPF300 (placebo), Dose form:CAPSULE, Route of administration:ORAL.J-POST Clinical Trial OfficeHokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima UniversityCompleted>=20 YEARSNo LimitBOTH24Japan

20. 副腎白質ジストロフィー [臨床試験数:49,薬物数:86(DrugBank:29),標的遺伝子数:18,標的パスウェイ数:112
Searched query = "Adrenoleukodystrophy", "Adrenomyeloneuropathy", "AMN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 49 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00004450August 199818/10/1999Randomized Study of Beta Interferon and Thalidomide in Patients With AdrenoleukodystrophyAdrenoleukodystrophyDrug: glyceryl trierucate;Drug: glyceryl trioleate;Drug: interferon beta;Drug: thalidomideFDA Office of Orphan Products DevelopmentHugo W. Moser Research Institute at Kennedy Krieger, Inc.Completed4 YearsN/AMale60N/ANULL

28. 全身性アミロイドーシス [臨床試験数:212,薬物数:234(DrugBank:72),標的遺伝子数:54,標的パスウェイ数:170
Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
8 / 212 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04612582January 1, 202015/6/2020Comparison of BTD and BCD Based Regimens in the Treatment of AL AmyloidosisA Comparative Study of Bortezomib-Thalidomide-Dexamethason and Bortezomib-Cyclophosphamide-Dexamethason in the Treatment of Monoclonal Immunoglobulin Light Chain Amyloidosis: A Prospective Randomized Controlled Trial(BTD-CHINA-TRIAL)Immunoglobulin Light-Chain AmyloidosisDrug: Thalidomide;Drug: CyclophosphamideGuangdong Provincial People's HospitalNULLRecruiting18 Years80 YearsAll70Phase 4China
2ChiCTR-IPR-170126372017-10-012017-09-11Prospective Randomized controlled study of the combination regimen of bortezomib + thalidomide + dexamethasone (VTD) and bortezomib + cyclophosphamide + dexamethasone (VCD) for the initial treatment of type AL amyloidosisProspective Randomized controlled study of the combination regimen of bortezomib + thalidomide + dexamethasone (VTD) and bortezomib + cyclophosphamide + dexamethasone (VCD) for the initial treatment of type AL amyloidosis type AL amyloidosisGroup 1:the combination regimen of bortezomib +thalidomide + dexamethasone (VTD);Group 2:the combination regimen of bortezomib + cyclophosphamide + dexamethasone (VCD);Guangdong General HospitalNULLPending1875BothGroup 1:35;Group 2:35;China
3ChiCTR-IPR-160084222016-05-052016-05-08Randomized controlled study of the combination regimen of bortezomib + cyclophosphamide + dexamethasone (BCD) and bortezomib +thalidomide + dexamethasone (BTD) for the initial treatment of primary systemic amyloidosis (AL)Randomized controlled study of the combination regimen of bortezomib + cyclophosphamide + dexamethasone (BCD) and bortezomib +thalidomide + dexamethasone (BTD) for the initial treatment of primary systemic amyloidosis (AL) primary systemic amyloidosis (AL)the first group: the combination regimen of bortezomib + cyclophosphamide + dexamethasone (BCD);the second group:the combination regimen of bortezomib +thalidomide + dexamethasone (BTD) ;People's Hospital, Beijing UniversityNULLRecruiting1875Boththe first group:60;the second group:60;China
4NCT02545907October 201527/8/2015A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL AmyloidosisA Single Arm Open Labeled Multicentre Phase 1b Dose Escalation Study of Carfilzomib Taken in Combination With Thalidomide and Dexamethasone in Relapsed AL AmyloidosisAmyloidosisDrug: Carfilzomib;Drug: Thalidomide;Drug: DexamethasoneUniversity College, LondonNULLNot yet recruiting18 YearsN/ABoth36Phase 1/Phase 2United Kingdom
5NCT01849783April 4, 20136/5/2013Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaSingle Autologous Transplant Followed by Consolidation and Maintenance for Participants = 65 Years of Age Diagnosed With Multiple Myeloma or a Related Plasma Cell MalignancyExtramedullary Plasmacytoma;Isolated Plasmacytoma of Bone;Light Chain Deposition Disease;Primary Systemic Amyloidosis;Stage I Multiple Myeloma;Stage II Multiple Myeloma;Stage III Multiple MyelomaDrug: dexamethasone;Drug: cisplatin;Drug: doxorubicin;Drug: cyclophosphamide;Drug: etoposide;Drug: bortezomib;Drug: thalidomide;Drug: melphalan;Procedure: autologous stem cell transplantYogesh JethavaNational Cancer Institute (NCI)Active, not recruiting65 Years85 YearsAll41Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00064337January 20048/7/2003S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic AmyloidosisS0115, A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m) And Autologous Peripheral Blood Stem Cell Supported Transplant (SCT) For High Risk Patients With Multiple Myeloma And/Or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study)Multiple Myeloma;Plasma Cell MyelomaBiological: filgrastim;Drug: cyclophosphamide;Drug: dexamethasone;Drug: melphalan;Drug: thalidomide;Procedure: peripheral blood stem cell transplantationSouthwest Oncology GroupNational Cancer Institute (NCI)Completed18 Years120 YearsAll104Phase 2United States
7NCT01527032September 200228/7/2011Risk-adapted Therapy for Primary Systemic (AL) AmyloidosisRisk-adapted Therapy for AL AmyloidosisAmyloidosisDrug: melphalan, thalidomide and dexamethasoneFDA Office of Orphan Products DevelopmentNULLCompletedPhase 2NULL
8NCT00089167May 20024/8/2004Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic AmyloidosisRisk Adapted Intravenous Melphalan and Adjuvant Thalidomide and Dexamethasone for Untreated Patients With Primary Systemic AmyloidosisMultiple Myeloma and Plasma Cell NeoplasmBiological: filgrastim;Drug: dexamethasone;Drug: melphalan;Drug: thalidomideMemorial Sloan Kettering Cancer Center.National Cancer Institute (NCI)Completed18 YearsN/ABothPhase 2United States

49. 全身性エリテマトーデス [臨床試験数:827,薬物数:638(DrugBank:168),標的遺伝子数:108,標的パスウェイ数:191
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 827 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03122431June 5, 201717/4/2017Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune DiseasesRelevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse EffectsSystemic Lupus Erythematosus (SLE);Juvenile SLE;Cutaneous LupusDrug: Thalidomide;Drug: Hydroxychloroquine reduced;Drug: Hydroxychloroquine highUniversity of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloRecruiting5 Years64 YearsAll296Phase 4Brazil

51. 全身性強皮症 [臨床試験数:466,薬物数:536(DrugBank:142),標的遺伝子数:110,標的パスウェイ数:210
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 466 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00418132August 20003/1/2007Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic SclerosisT Cell Immunity in Collagen Biosynthesis of SclerodermaScleroderma, SystemicDrug: Thalidomide;Drug: Placebo thalidomideNew York University School of MedicineNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Terminated18 Years65 YearsBoth30Phase 1United States

53. シェーグレン症候群 [臨床試験数:234,薬物数:270(DrugBank:85),標的遺伝子数:49,標的パスウェイ数:174
Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 234 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00001599May 19973/11/1999Pilot Study of Thalidomide to Treat Sjogren's SyndromePilot Study of Thalidomide for Sjogren's SyndromeSjogren's Syndrome;XerostomiaDrug: ThalidomideNational Institute of Dental and Craniofacial Research (NIDCR)NULLCompletedN/AN/AFemale28Phase 2United States

56. ベーチェット病 [臨床試験数:68,薬物数:87(DrugBank:31),標的遺伝子数:36,標的パスウェイ数:113
Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 68 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR20000371722021-01-012020-08-27Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's DiseaseRandomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease Behcet's Diseaseexperimental group:Shen's Qinlian Soil Fuling Granules + Thalidomide Tablets;control group:placebo + Thalidomide Tablets ;Shanghai Traditional Chinese Medicine HospitalNULLPending1670Bothexperimental group:60;control group:60;China

65. 原発性免疫不全症候群 [臨床試験数:413,薬物数:581(DrugBank:97),標的遺伝子数:68,標的パスウェイ数:202
Searched query = "Primary immunodeficiency", "X-SCID", "Reticular dysgenesis", "Adenosine deaminase deficiency", "Omenn syndrome", "Purine nucleoside phosphorylase deficiency", "CD8 deficiency", "ZAP-70 deficiency", "MHC class I deficiency", "MHC class II deficiency", "Combined immunodeficiency", "Wiskott-Aldrich syndrome", "Telangiectasia ataxia", "Nijmegen breakage syndrome", "Bloom syndrome", "Immunodeficiency, centromere region instability, facial anomalies syndrome", "ICF syndrome", "PMS2 deficiency", "Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome", "RIDDLE syndrome", "Schimke syndrome", "Netherton syndrome", "Thymic hypoplasia", "DiGeorge syndrome", "22q11.2 deletion syndrome", "Hyper-IgE syndrome", "Hepatic venoocclusive immunodeficiency", "Immunodeficiency with central hepatic vein atresia", "Dyskeratosis congenita", "X-linked agammaglobulinaemia", "Common variable immunodeficiency", "Hyper-IgM syndrome", "Isolated IgG subclass deficiency", "Selective IgA deficiency", "Specific antibody production deficiency", "Infant transient hypogammaglobulinemia", "Chédiak-Higashi syndrome", "Chediak-Higashi syndrome", "X-linked lymphoproliferative syndrome", "SAP deficiency", "SH2D1A/SLAM-associated protein deficiency", "XIAP deficiency", "X-linked inhibitor of apoptosis deficiency", "Autoimmune lymphoproliferative syndrome", "ALPS", "Familial hemophagocytic syndrome", "Perforin deficiency", "Munc13-4 deficiency", "Syntaxin 11 deficiency", "Munc18-2 deficiency", "Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy", "APECED", "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome", "IPEX syndrome", "CD25 deficiency", "ITCH deficiency", "Primary phagocytic dysfunction", "Severe congenital neutropenia", "Cyclic neutropenia", "Hermanskyi-Pudlak syndrome type 2", "Hermanskyi-Pudlak syndrome 2", "Griscelli syndrome type 2", "Griscelli syndrome 2", "p14 deficiency", "Warts, hypogammaglobulinemia, infections, myelokathexis syndrome", "WHIM syndrome", "Glycogen storage disease type Ib", "Leukocyte adhesion deficiency", "Shwachman-Diamond syndrome", "Chronic granulomatous disease", "Myeloperoxidase deficiency", "Mendelian susceptibility to mycobacterial disease", "MSMD", "Anhidrotic ectodermal dysplasia with immunodeficiency", "EDA-ID", "Interleukin-1 receptor-associated kinase-4 deficiency", "IRAK4 deficiency", "IMyD88 deficiency", "Chronic mucocutaneous candidiasis", "Epidermodysplasia verruciformis", "Herpes simplex encephalitis", "Caspase recruitment domain family member 9 deficiency", "CARD9 deficiency", "Trypanosomiasis", "Congenital complement deficiency", "C1q deficiency", "CC1r deficiency", "CC1s deficiency", "CC2 deficiency", "CC3 deficiency", "CC4 deficiency", "CC5 deficiency", "CC6 deficiency", "CC7 deficiency", "CC8 deficiency", "CC9 deficiency", "Factor D deficiency", "Properdin deficiency", "Factor I deficiency", "Factor H deficiency", "MASP1 deficiency", "3MC syndrome", "Mannose-binding protein-associated serine protease 2 deficiency", "MASP2 deficiency", "FCN3", "Hereditary angioedema type 1", "Hereditary angioedema type I", "C1 inhibitor deficiency type 1", "C1 inhibitor deficiency type I", "Hereditary angioedema type 2", "Hereditary angioedema type II", "C1 inhibitor deficiency type 2", "C1 inhibitor deficiency type II", "Hereditary angioedema type 3", "Hereditary angioedema type III", "C1 inhibitor deficiency type 3", "C1 inhibitor deficiency type III"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 413 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT203120023628/09/201710/12/2020Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitisDouble-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis chronic granulomatous disease-associated colitis
primary immunodeficiency diseases; inflammatory bowel disease;D006105
1) Oral administration of thalidomide (1.5-3mg/kg), once a day
2) Oral administration of placebo (1.5-3mg/kg), once a day
Kawai ToshinaoKawai Toshinao;Japan Agency for Medical Research and DevelopmentRecruiting>= 1age oldNot applicableBoth8Japan
2JPRN-UMIN0000293242017/09/2801/10/2017Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitisDouble-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis - Clinical trial of thalidomide for CGD colitis Chronic granulomatous disease associated colitisOral administration of thalidomide (1.5-3mg/kg), once a day
Oral administration of placebo (1.5-3mg/kg), once a day
National Center for Child Heath and DevelopmentNULLRecruiting1years-oldNot applicableMale and Female8Not selectedJapan
3JPRN-UMIN0000093702012/12/0721/11/2012Thalidomide therapy clinical trial for chronic granulomatous disease-associated intractable granulomatous lesion Chronic granulomatous diseaseOral administration of thalidomideNational Center for Child Heath and DevelopmentNULLComplete: follow-up complete3years-oldNot applicableMale and Female5Not selectedJapan

84. サルコイドーシス [臨床試験数:143,薬物数:221(DrugBank:79),標的遺伝子数:82,標的パスウェイ数:165
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 143 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00305552February 200521/3/2006SARCOTHAL. Thalidomide in Skin SarcoidosisRandomized Controlled Trial of Thalidomide vs Placebo in Skin SarcoidosisSarcoidosisDrug: THALIDOMIDEAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/ABoth40Phase 3France

85. 特発性間質性肺炎 [臨床試験数:514,薬物数:377(DrugBank:108),標的遺伝子数:97,標的パスウェイ数:204
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 514 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-023828-24-GB09/06/201127/04/2011The effect of Thalidomide on sputum biomarkers in IPF cough. - The effect of Thalidomide on sputum biomarkers in IPF coughThe effect of Thalidomide on sputum biomarkers in IPF cough. - The effect of Thalidomide on sputum biomarkers in IPF cough Cough in Idiopathic Pulmonary fibrosis.Trade Name: Thalidomide Pharmion
Product Name: Thalidomide Pharmion
Trade Name: PREDNISOLONE
Product Name: prednisolone
University of NottinghamNULLNot RecruitingFemale: yes
Male: yes
United Kingdom
2NCT00600028December 200711/1/2008Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With ThalidomideTreatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With ThalidomideIdiopathic Pulmonary Fibrosis;CoughDrug: Thalidomide;Drug: PlaceboJohns Hopkins UniversityNULLCompleted50 YearsN/AAll25Phase 3United States
3NCT00162760October 20038/9/2005Treatment of Idiopathic Pulmonary Fibrosis With ThalidomideTreatment of Idiopathic Pulmonary Fibrosis With ThalidomideIdiopathic Pulmonary Fibrosis (IPF)Drug: ThalidomideJohns Hopkins UniversityCelgene CorporationCompleted50 Years80 YearsBoth19Phase 2United States

94. 原発性硬化性胆管炎 [臨床試験数:134,薬物数:105(DrugBank:37),標的遺伝子数:18,標的パスウェイ数:131
Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 134 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00953615April 20064/8/2009Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)Open Label, Phase II Investigation of Thalidomide for the Treatment of Primary Sclerosing CholangitisPrimary Sclerosing CholangitisDrug: ThalidomideMayo ClinicCelgene CorporationTerminated18 Years72 YearsAll1Phase 2United States

96. クローン病 [臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
8 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03221166February 27, 20185/7/2017Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic FactorsThalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research NetworkCrohn DiseaseDrug: Thalidomide;Drug: InfliximabIRCCS Burlo GarofoloCentro di Riferimento Oncologico - Aviano;Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaTerminated6 Years17 YearsAll9Phase 3Italy
2EUCTR2016-000786-24-IT07/03/201730/11/2016Efficacy and safety of thalidomide in pediatric patients with Crohn's diseaseThalidomide, a novel immunological treatment to modify the natural history of paediatric Crohn's disease: a new proposal from a well-established paediatric research network - Talidomide in Crohn disease in Pediatrics Crohn's Disease
MedDRA version: 19.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
IRCCS Burlo GarofoloNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
124 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): no Therapeut1c conf1rmatory - (Phase 3): yes Therapeut1c use (Phase 4): noItaly
3NCT02998827November 201624/11/2016Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD PatientsCrohn DiseaseDrug: Thalidomide;Drug: infliximab, azathioprine;Other: enteral nutritionSixth Affiliated Hospital, Sun Yat-sen UniversityNULLEnrolling by invitationN/AN/AFemale90N/ANULL
4NCT02956538October 201613/10/2016Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using ThalidomideInduced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide: A Randomized, Double-blind, Placebo-controlled Multicenter Clinical StudyCrohn DiseaseDrug: Thalidomide;Drug: placebo(for thalidomide)Sixth Affiliated Hospital, Sun Yat-sen UniversityNULLRecruiting18 Years50 YearsBoth72Phase 0China
5ChiCTR-OPC-160086552016-05-012016-06-16Efficacy and safety of thalidomide for patients with Crohn's Disease: a prospective multicenter observational study from ChinaEfficacy and safety of thalidomide for patients with Crohn's Disease: a prospective multicenter observational study from China Crohn‘s Disease1:Thalidomide 75-100mg qd;2:Thalidomide 150-200mg qd;3:Thalidomide 75-100mg qd+MTX 20-25mg /W;Peking Union Medical College HospitalNULLRecruiting1670Both1:90;2:90;3:90;China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02501291January 201320/5/2015Thalidomide in Treating Crohn's DiseaseThalidomide in Inducing and Maintaining Remission of Crohn's DiseaseCrohn's DiseaseDrug: ThalidomideFirst Affiliated Hospital, Sun Yat-Sen UniversityNULLCompleted18 Years75 YearsBoth47Phase 2China
7NCT00720538August 200818/7/2008Thalidomide in Pediatric Inflammatory Bowel Diseases.Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis.Inflammatory Bowel Diseases;Crohn's Disease;Ulcerative ColitisDrug: Thalidomide;Drug: placeboIRCCS Burlo GarofoloOspedale Meyer;Pediatric Gastroenterology Unit, IRCCS Gaslini, Genoa.;Vittore Buzzi Children's Hospital;University of Pisa;Pediatric Gastroenterology Unit, University of Messina.;Università degli Studi di Brescia;University of TriesteCompleted2 Years18 YearsBoth84Phase 3Italy
8EUCTR2005-005414-20-IT06/03/200631/01/2006Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBDRandomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD Inflammatory Bowel Disease Crohn Disease, Ulcerative Colitis
MedDRA version: 6.1Level: PTClassification code 10021972
Trade Name: Thalidomide Pharmion
INN or Proposed INN: Thalidomide
ISTITUTO PER L INFANZIA BURLO GAROFOLONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
124Italy

97. 潰瘍性大腸炎 [臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,269 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00720538August 200818/7/2008Thalidomide in Pediatric Inflammatory Bowel Diseases.Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis.Inflammatory Bowel Diseases;Crohn's Disease;Ulcerative ColitisDrug: Thalidomide;Drug: placeboIRCCS Burlo GarofoloOspedale Meyer;Pediatric Gastroenterology Unit, IRCCS Gaslini, Genoa.;Vittore Buzzi Children's Hospital;University of Pisa;Pediatric Gastroenterology Unit, University of Messina.;Università degli Studi di Brescia;University of TriesteCompleted2 Years18 YearsBoth84Phase 3Italy
2EUCTR2005-005414-20-IT06/03/200631/01/2006Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBDRandomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD Inflammatory Bowel Disease Crohn Disease, Ulcerative Colitis
MedDRA version: 6.1Level: PTClassification code 10021972
Trade Name: Thalidomide Pharmion
INN or Proposed INN: Thalidomide
ISTITUTO PER L INFANZIA BURLO GAROFOLONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
124Italy

227. オスラー病 [臨床試験数:49,薬物数:69(DrugBank:21),標的遺伝子数:23,標的パスウェイ数:132
Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 49 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01485224November 201128/11/2011Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic TelangiectasiaEfficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia;EpistaxisDrug: ThalidomideIRCCS Policlinico S. MatteoNULLCompleted18 YearsN/AAll31Phase 2Italy
2EUCTR2011-004096-36-IT11/10/201119/03/2012Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasiaEfficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT) Severe recurrent epistaxis in hereditary hemorrhagic telangiectasia
MedDRA version: 14.1Level: LLTClassification code 10038554Term: Rendu-Osler-Weber syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: THALIDOMIDE CELGENE*28CPS 50MG
INN or Proposed INN: THALIDOMIDE
OSPEDALE POLICLINICO S. MATTEONULLNot RecruitingFemale: yes
Male: yes
31Phase 2Italy
3NCT00389935October 200617/10/2006Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingThalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingArteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;MelenaDrug: ThalidomideNorthport Veterans Affairs Medical CenterGeorgia Regents University;University of Massachusetts, WorcesterCompleted18 YearsN/ABoth14Phase 2United States

271. 強直性脊椎炎 [臨床試験数:531,薬物数:343(DrugBank:66),標的遺伝子数:41,標的パスウェイ数:141
Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 531 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-TRC-130034492013-04-252013-06-07A multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomide in the treatment of Ankylosing SpondylitisA multicenter, randomized, double-blind, placebo-controlled, Phase II clinical study of Thalidomide in the treatment of Ankylosing Spondylitis Ankylosing SpondylitisThalidomide 150mg:Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd, po., to the end;Thalidomide 100mg:Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end;Control group:Placebo po.;The General Hospital of People's Liberation ArmyNULLCompleted1865BothThalidomide 150mg:80;Thalidomide 100mg:80;Control group:40;2 (Phase 2 study)China
2NCT02201043February 201323/7/2014Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing SpondylitisA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing SpondylitisAnkylosing SpondylitisDrug: Thalidomide 150mg;Drug: Thalidomide 100mg;Drug: PlaceboShanghai Pharmaceuticals Holding Co., LtdNULLCompleted18 Years65 YearsBoth197Phase 2China
3ChiCTR-ONRC-100008582010-05-102010-04-28Research on safety tolerance and pharmacokinetics of oral muti-dose ThalidomideResearch on safety tolerance and pharmacokinetics of oral muti-dose Thalidomide Ankylosing SpondylitisGroup A:Muti-dose Thalidomide;GroupB:Muti-dose Thalidomide and Diclofenac sodium enteric-coated tablets ;Chinese PLA General HospitalNULLCompleted1845BothGroup A:15;GroupB:12;1 (Phase 1 study)China
4ChiCTR-ONRC-110018462009-12-032011-12-28The research of immue state and current treatment in Ankylosing spondylitisThe research of immue state and current treatment in Ankylosing spondylitis Ankylosing spondylitisTraditional therapy group:DMARDs;biological agent group:biological agent;thalidomide group:thalidomide;Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical UniversityNULLCompleted1865BothTraditional therapy group:500;biological agent group:500;thalidomide group:500;NULL

280. 巨大動静脈奇形(頚部顔面又は四肢病変) [臨床試験数:22,薬物数:26(DrugBank:13),標的遺伝子数:11,標的パスウェイ数:147
Searched query = "Huge arteriovenous malformation with cervicofacial or limb lesion", "Huge arteriovenous malformation", "Arteriovenous malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 22 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR19000219012019-03-202019-03-15Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot StudyEfficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study central nervous system arteriovenous malformationsCase series:Oral thalidomide;Xuanwu Hospital, Capital Medical UniversityNULLCompletedBothCase series:30;China
2NCT00389935October 200617/10/2006Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingThalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingArteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;MelenaDrug: ThalidomideNorthport Veterans Affairs Medical CenterGeorgia Regents University;University of Massachusetts, WorcesterCompleted18 YearsN/ABoth14Phase 2United States

298. 遺伝性膵炎 [臨床試験数:93,薬物数:168(DrugBank:51),標的遺伝子数:48,標的パスウェイ数:134
Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 93 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00469703August 20053/5/2007Safety and Efficacy Study of Thalomid in Patients With Chronic PancreatitisA Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis.Chronic PancreatitisDrug: ThalidomideWinthrop University HospitalCelgene CorporationTerminated18 Years75 YearsBoth10Phase 2United States

300. IgG4関連疾患 [臨床試験数:31,薬物数:33(DrugBank:16),標的遺伝子数:11,標的パスウェイ数:81
Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 31 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR20000289182020-01-012020-01-07A randomized, double-blind controlled study of glucocorticoids combination with thalidomide in the treatment of IgG4-related diseasesEfficacy and safety of thalidomide in IgG4-related diseases IgG4 related diseasecontrol group:prednison combined with placebo;experimental group:prednison combined with thalidomide;Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNULLRecruiting1880Bothcontrol group:51;experimental group:51;China

331. 特発性多中心性キャッスルマン病 [臨床試験数:30,薬物数:44(DrugBank:23),標的遺伝子数:30,標的パスウェイ数:148
Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 30 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03043105January 1, 201731/1/2017TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot TrialThalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot TrialMulticentric Castleman DiseaseDrug: Thalidomide, cyclophosphamide and prednisonePeking Union Medical College HospitalNULLActive, not recruiting18 YearsN/AAll25Phase 2China